Sugi Predict

Sugi Predict / Compounds / SCHEMBL21333082

SCHEMBL21333082

SCHEMBL21333082

C#Cc1ccc(=O)n(CC(=O)c2cnn(Cc3cccc(C(=O)O)c3)c2C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ S1PR2 O95136 1/20 0.39
▸ IDO1 P14902 2/20 0.38
▸ TDO2 P48775 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ MET P08581 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ TAS2R8 Q9NYW2 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ MKNK1 Q9BUB5 2/20 0.35
▸ MKNK2 Q9HBH9 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30866462 1.00 KMT2A (0.40) KMT2ASMN1; SMN2POLBTDP1L3MBTL1
SCHEMBL21333548 0.90 S1PR2 (0.45) KMT2ASMN1; SMN2S1PR2KDM4EALDH1A1
SCHEMBL21333033 0.88 CREBBP (0.42) KMT2ASMN1; SMN2L3MBTL1S1PR2MET
SCHEMBL21333435 0.86 KMT2A (0.42) KMT2ASMN1; SMN2POLBTDP1L3MBTL1
SCHEMBL30866465 0.86 KMT2A (0.42) KMT2ASMN1; SMN2POLBTDP1L3MBTL1
SCHEMBL21333291 0.84 KDM4E (0.37) KMT2ASMN1; SMN2S1PR2HIF1AKDM4E
SCHEMBL21332838 0.82 PTGDR2 (0.41) KMT2APOLBS1PR2HTTKDM4E
SCHEMBL21332993 0.80 ABHD6 (0.42) KMT2ASMN1; SMN2POLBS1PR2IDO1
SCHEMBL21332937 0.79 KDM4E (0.45) KMT2ASMN1; SMN2POLBS1PR2KDM4E
SCHEMBL22831429 0.78 KMT2A (0.41) KMT2ASMN1; SMN2S1PR2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762377-B1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF UNIV CORNELL (US) 2025-08-20 — — EP disclosed
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof CORNELL UNIVERSITY (US) 2024-04-23 — — US disclosed
EP-3762377-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF Cook, Timothy, H. (US) 2021-01-13 — — EP disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 — — US disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 — — US disclosed
WO-2019173790-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF HLA TIMOTHY (US) 2019-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF PTGER1, LOXL1, COL1A1 KMT2A 4385/4885SMN1; SMN2 3979/4885POLB 3175/4885
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof PTGER1, LOXL1, COL1A1 KMT2A 4385/4885SMN1; SMN2 3979/4885POLB 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.